Investing.com - Dynavax (NASDAQ: DVAX) reported fourth quarter EPS of $0.000, $0.03 better than the analyst estimate of $-0.030. Revenue for the quarter came in at $55.59M versus the consensus estimate of $52.4M.
Guidance
Dynavax sees FY 2024 revenue of $265.000M-$280.000M versus the analyst consensus of $290.600M.
Dynavax's stock price closed at $12.440. It is down -8.260% in the last 3 months and up 20.080% in the last 12 months.
Dynavax saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Dynavax's stock price’s past reactions to earnings here.
According to InvestingPro, Dynavax's Financial Health score is "great performance".
Check out Dynavax's recent earnings performance, and Dynavax's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar